Nightstar Therapeutics to Participate in Multiple Conferences in November
(Thomson Reuters ONE) -
LEXINGTON, Mass. and LONDON, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Nightstar
Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing
treatments for rare inherited retinal diseases, today announced that the company
will participate in the following industry and investor conferences in
November:
* Ophthalmology Innovation Summit on Thursday, November 9, 2017 at 8:54 a.m.
ET in New Orleans
* Jefferies London Healthcare Conference on Thursday, November 16, 2017 at
2:40 p.m. GMT in London
* Barclays Gene Editing & Gene Therapy Summit on Thursday, November 30, 2017
at 11 a.m. ET in New York City
The presentation at the Jefferies London Healthcare Conference will be webcast
live and available for replay at ir.nightstartx.com.
About Nightstar
Nightstar is a leading clinical-stage gene therapy company focused on developing
and commercializing novel one-time treatments for patients suffering from rare
inherited retinal diseases that would otherwise progress to blindness.
Nightstar's lead product candidate, NSR-REP1, is being developed as a treatment
for patients with choroideremia, a rare, degenerative, genetic retinal disorder
that has no current treatments and affects approximately one in every 50,000
people. Positive results from a Phase 1/2 trial of NSR-REP1 were published
in The Lancet in 2014 and in The New England Journal of Medicine in 2016.
Nightstar plans to commence a Phase 3 registrational trial of NSR-REP1 for
choroideremia at sites in the United States, Europe and Canada in the first half
of 2018. Nightstar's second product candidate, NSR-RPGR, is currently being
evaluated in a Phase 1/2 clinical trial for the treatment of patients with X-
linked retinitis pigmentosa, an inherited X-linked recessive retinal disease
that affects approximately one in every 40,000 people.
For more information about Nightstar or its clinical trials, please
visit www.nightstartx.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including, but not limited
to: statements about our plans to develop and commercialize our product
candidates, our planned clinical trials for NSR-REP1 and NSR-RPGR, the clinical
utility of our product candidates, the prevalence of patient populations for our
targeted indications, and the utility of prior preclinical and clinical data in
determining future clinical results. These forward-looking statements are based
on management's current expectations of future events and are subject to a
number of involve substantial known and unknown risks, uncertainties and other
factors that may cause our actual results, levels of activity, performance or
achievements to be materially different from the information expressed or
implied by these forward-looking statements, including the risks and
uncertainties set forth in the "Risk Factors" section of our prospectus filed
pursuant to Rule 424(b)(4) under the U.S. Securities Act of 1933, as amended, on
September 28, 2017, and subsequent reports that we file with the U.S. Securities
and Exchange Commission. We may not actually achieve the plans, intentions or
expectations disclosed in our forward-looking statements, and you should not
place undue reliance on our forward-looking statements. Actual results or events
could differ materially from the plans, intentions and expectations disclosed in
the forward-looking statements we make. The forward-looking statements in this
presentation represent our views as of the date of this presentation. We
anticipate that subsequent events and developments will cause our views to
change. However, while we may elect to update these forward-looking statements
at some point in the future, we have no current intention of doing so except to
the extent required by applicable law. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date subsequent
to the date of this presentation.
Contact:
Senthil Sundaram, Chief Financial Officer
investors(at)nightstartx.com
Alicia Davis, THRUST IR
910-620-3302
alicia(at)thrustir.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nightstar Therapeutics via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 30.10.2017 - 21:05 Uhr
Sprache: Deutsch
News-ID 565884
Anzahl Zeichen: 5047
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 216 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nightstar Therapeutics to Participate in Multiple Conferences in November"
steht unter der journalistisch-redaktionellen Verantwortung von
Nightstar Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
